Is petrelintide approved?

No. It is investigational, with published human data at phase 1. There is no approval and no prescription route anywhere.

Is petrelintide the same as cagrilintide?

No, but they are the same class. Both are long-acting amylin analogs designed for weekly dosing; petrelintide is Zealand Pharma's and cagrilintide is Novo Nordisk's, and cagrilintide is much further along.

Is petrelintide a GLP-1?

No. It acts on amylin receptors, a separate hormone system. That is the point of the class — a different mechanism, with the hope of better tolerability.

What Is Petrelintide? Amylin Analog, Phase 1 Evidence (2026)

Petrelintide is an investigational long-acting human amylin analog from Zealand Pharma. Like cagrilintide, it acts on the amylin system rather than the GLP-1 system — a genuinely different mechanism, not a stronger version of the drugs already on the market ^[3]. It is at an earlier stage than most compounds people search for: the published human data are phase 1 ^[2], and it has no approval anywhere.

What amylin analogs are for

Amylin is released with insulin from pancreatic beta cells and reduces meal size through its own receptor pathway. The interest in analogs of it is partly about added weight loss and substantially about tolerability: the search for better-tolerated weight-loss drugs is the explicit framing in the review literature ^[3], because GLP-1 discontinuation is frequently driven by gastrointestinal side effects rather than lack of effect.

Petrelintide was engineered for potency, stability and a long half-life so it can be dosed weekly ^[1] — the same design problem cagrilintide solves, approached by a different company.

How early is early

The published clinical evidence is two randomized, controlled phase 1 trials reporting safety, tolerability, pharmacokinetics and pharmacodynamics for weight management ^[2]. Phase 1 trials are designed to answer whether a drug is tolerable and how the body handles it — not whether it works better than an existing treatment.

What phase 1 cannot tell you. Weight-loss percentages quoted from early-phase work are not comparable to the phase 3 figures you have seen for semaglutide or tirzepatide. Different sample sizes, durations, and endpoints — and early-phase estimates move, often downward, as trials get larger. Treat any petrelintide-versus-Wegovy comparison as speculation.

It is not available, in any form

Petrelintide has no approval and no prescription route. As with every unapproved compound in this class, anything offered for sale under the name is unapproved material rather than a trial drug — and at phase 1, the total human safety experience is smaller than for almost anything else being sold that way.

Frequently Asked Questions

References

1.Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, et al. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem. 2025. PMID: 41217931.
2.Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026. PMID: 42017294.
3.Alhazmi A, le Roux CW. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab. 2026. PMID: 42452898.

What Is Cagrilintide? The Amylin Analog Behind CagriSema

Cagrilintide is a once-weekly amylin analog from Novo Nordisk and the other half of CagriSema. Neither has FDA approval. We cover what amylin analogs actually are, the pooled trial evidence across 5,425 participants, and why there is no cagrilintide dosage chart to follow.

6 min read

Cagrilintide: The Amylin Analogue Behind CagriSema — What the Evidence Shows

Cagrilintide is Novo Nordisk's investigational long-acting amylin analog and the amylin half of CagriSema. The phase 2 monotherapy trial showed about -10.8% weight loss at 26 weeks. What it is, the trial data, and what it means for patients.

8 min read

REDEFINE: The Full CagriSema Trial Program (2026)

The full CagriSema REDEFINE program: REDEFINE 1 (22.7% adherent weight loss), REDEFINE 2 in diabetes, and the REDEFINE 4 head-to-head miss versus tirzepatide.

13 min read

Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs That Could Reach Approval in 2026-2027

Survodutide (Boehringer Ingelheim/Zealand), maridebart cafraglutide (MariTide, Amgen), and ecnoglutide (Sciwind/Pfizer) are the three most-watched GLP-1 pipeline drugs that aren't being made by Lilly or Novo. We walk through the verified phase 2 and phase 3 data on each, the mechanisms, and where they fit in the post-CagriSema, post-retatrutide landscape.

11 min read

Bimagrumab: The Muscle-Preserving Weight-Loss Antibody — Evidence Review

Bimagrumab is an investigational antibody that blocks ActRII to build muscle while cutting fat — the opposite of GLP-1 muscle loss. Phase 2 evidence: -20.5% fat, +3.6% lean, plus the BELIEVE bimagrumab + semaglutide trial.

9 min read

CagriSema REDEFINE: What Novo Nordisk's Amylin Combination Actually Showed

CagriSema (cagrilintide + semaglutide) is Novo Nordisk's next-generation amylin-GLP-1 combination injection. We walk through the REDEFINE 1 and REDEFINE 2 phase 3 trial results — 22.7% adherent weight loss in non-diabetic patients, 15.7% in patients with type 2 diabetes — and explain why the result missed the 25% target Novo had guided to but still beat semaglutide alone.

13 min read

What Is Petrelintide? Zealand's Long-Acting Amylin Analog

What amylin analogs are for

How early is early

It is not available, in any form

Frequently Asked Questions

References

Where to get GLP-1 safely: vetted online providers

GobyMeds

Direct Meds

Maximus

What amylin analogs are for

How early is early

It is not available, in any form

Frequently Asked Questions

References

Related research

Where to get GLP-1 safely: vetted online providers

GobyMeds

Direct Meds

Maximus